Pharmaceutical and Clinical Trials

Duke works closely with rheumatologists and doctors throughout the Southeast to offer patients access to new therapies through participation in carefully designed clinical trials.

The following list shows the current clinical research trials being conducted in our division and links to their profile on the clinicaltrials.gov Web site.

Study Evaluating the SBI-087 in Subjects With Systemic Lupus Erythematosus

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with systemic lupus erythematosus (SLE).

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic and signs of bioactivity of increasing single doses and repeated doses of AGS-009 in patients with systemic lupus erythematosus (SLE).

Study of Epratuzumab in Systemic Lupus Erythematosus

The purpose of the study is to obtain additional long-term information regarding the safety and efficacy of continued maintenance-cycle administrations of epratuzumab.

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

The primary objective of the study is to assess the safety of epratuzumab in patients with systemic lupus erythematosus (SLE).

Vitamin D3 in Systemic Lupus Erythematosus

The purpose of this study is to explore the impact of vitamin D3 on the expression of alpha interferon (IFN alpha) expression in systemic lupus erythematosus (SLE) patients with vitamin D deficiency.

Wegener’s Granulomatosis Etanercept Trial (WGET)

This trial examined ovarian function in women included in WGET (Wegener's Granulomatosis Etanercept Trial). This data has been presented at the 2009 ACR meeting, and demonstrated that cyclophosphamide is associated with a rapid and dramatic decline in ovarian reserve.